Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne disease 34 caused by SFTS virus (SFTSV) infection. Despite a gradual increase of SFTS cases and high 35 mortality in endemic regions, no specific viral therapy nor vaccine is available. Here, we 36 developed a single recombinant plasmid DNA encoding SFTSV genes, Gn and Gc together 37 with NP-NS fusion antigen, as a vaccine candidate. The viral antigens were fused with Fms-38 like tyrosine kinase-3 ligand (Flt3L) and IL-12 gene was incorporated into the plasmid to 39 enhance cell-mediated immunity. Vaccination with the DNA provides complete protection of 40 IFNAR KO mice upon lethal SFTSV challenge, whereas immunization with a plasmid 41 without IL-12 gene resulted in partial protection. Since we failed to detect antibodies against 42 surface glycoproteins, Gn and Gc, in the immunized mice, antigen-specific cellular immunity, 43 as confirmed by enhanced antigen-specific T cell responses, might play major role in 44 protection. Finally, we evaluated the degree of protective immunity provided by protein 45 immunization of the individual glycoprotein, Gn or Gc. Although both protein antigens 46 induced a significant level of neutralizing activity against SFTSV, Gn vaccination resulted in 47 relatively higher neutralizing activity and better protection than Gc vaccination. However, 48 both antigens failed to provide complete protection. Given that DNA vaccines have failed to 49 induce sufficient immunogenicity in human trials when compared to protein vaccines, 50 optimal combinations of DNA and protein elements, proper selection of target antigens, and 51 incorporation of efficient adjuvant, need to be further investigated for SFTSV vaccine 52 development.
Introduction 81
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging tick-borne infectious 82 disease caused by SFTS virus (SFTSV), belonging to the Phenuiviridae family of 83 Bunyavirales [1, 2] . The genome of SFTSV is composed of three segmented RNAs: large (L) 84 segment encoding RNA-dependent RNA polymerase (RdRp), medium (M) encoding the 85 envelop glycoproteins, Gn/Gc, and small (S) encoding the nucleocapsid and nonstructural 86 proteins (NP and NS) [1] . Clinical manifestations include fever, gastrointestinal symptoms, 87 leukocytopenia, and thrombocytopenia [3, 4] . Disease mortality of SFTS patients has been 88 estimated to be 5 ~ 20% [3] . Even though the majority of SFTS cases has been reported from 89 China [3] , Korea [4] , and Japan [5] , SFTSV infections in southern Asia, including Vietnam, 90 have been recently reported in a retrospective survey [6] . Currently, no specific viral therapy 91 nor vaccine is available. An effective vaccine is needed to combat its relatively high mortality, 92 especially in elderly patients, and spread of SFTSV between humans [7, 8] . 93 Vaccine development for SFTS is at an early discovery phase and there have only been a few 94 studies on vaccine candidates using animal infection models [8] [9] [10] [11] . Immunization of NS 95 antigen with Freund's adjuvant in C57BL/6 mice, which are naturally resistant to SFTSV but 96 partially mimic human infections [12] , failed to enhance viral clearance, although it induced 97 high titer of anti-NS antibodies and significantly elevated IFN- levels in sera upon viral In order to generate plasmids for DNA vaccination, genes encoding ectodomains of Gn, Gc 141 (from Genebank accession no. AJO16082.1), and NP/NS fusion protein (from Genebank 142 accession no. AJO16088.1 and AKI34298.1, respectively) were synthesized (GenScript, 143 Piscataway, NJ, USA) and cloned into pGX27 vector (Genexine, Seongnam, Republic of 144 Korea). All these genes were fused with signal peptide of tissue Plasminogen Activator (tPA, 145 Uniport no. P00750) and Flt3L (Uniport no. P49771) in their N-terminus [15] (pSFTSV, Fig   146   1 ). In addition, murine IL-12α and β genes (Uniport no. P43432) [17] were also synthesized 147 (GenScript) and cloned into pSFTSV (pSFTSV-IL-12, Fig 1) .
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Gene expression of plasmid DNAs
150
To confirm the expression of cloned genes in pSFTSV and pSFTSV-IL12, HEK 293T cells Gc, Gn, and NP/NS fusion protein in the culture supernatants and cell lysates were examined 165 by immunoblotting using rabbit anti-Gn, Gc (NBP2-41153 and NBP2-41156, NOVUS 166 Biologicals, Centennial, Colorado, USA), and NP (produced by custom polyclonal antibody 167 production service via Abclon, Seoul, Republic of Korea) antibodies, respectively. Each 168 sample was separated on 8% polyacrylamide gels and transferred onto 0.45 µm PVDF 169 membranes (Merck, Darmstadt, Germany). PVDF membranes were blocked with PBS 170 containing 0.05% Tween 20 (PBST) and 5% skim milk at room temperature for 2 h. The 171 membranes were sequentially incubated with primary and secondary antibodies conjugated 172 with horse radish peroxidase (HRP, Invitrogen, Waltham, MA, USA). The membranes were 173 then visualized using a LAS-4000 system (Fujifilm, Tokyo, Japan). 176 The gene encoding the NP of the KASJH strain (Genbank Accession No. KP663733) was 177 cloned into the pET28a (+) vector (Novagen, Gibbstown, NJ, USA). NP protein was then 178 purified from E. coli strain BL21 (DE3) harboring the recombinant plasmid. Following 179 induction with 0.1 mM isopropyl β-D-thiogalactoside (IPTG) for 18 h at 16℃, the protein 180 was purified using HisTrap HP histidine-tagged protein columns (GE healthcare, Chicago, IL, Overexpressed recombinant proteins in supernatants were purified by AKTA start affinity Neutralizing antibody assay 239 To evaluate the neutralizing activity of immune sera, a focus reduction neutralization titer 240 (FRNT) assay was performed using immunized mice sera [21] . SFTSV (0.0001 multiplicity 241 of infection) was pre-incubated with serially diluted sera from mice at 4℃ for 1 h. The 242 mixture of virus and sera was added onto a monolayer of Vero E6 cells in 24-well plate. After 243 incubation for 2 h, supernatant of cells were removed and cells were cultured under an 244 overlay media at 37℃ for 7 days. Viral foci were visualized as described above. The confirmed by ELISA and immunoblot analysis (Fig. 2) . All the viral antigens were detected 312 in cell culture supernatants, as well as in cellular lysates (Fig. 2B) . x 10 5 FFU (S3 Fig A) . Upon infection, all the mice gradually lost body weight and became 376 moribund from the third to fifth day after infection, depending on the infection dose. All the 377 infected mice died at 5 ~ 9 d after infection (S3 Fig A) . Similar survival kinetics were 378 previously reported in IFNAR KO mice infected with other SFTSV strains [11, 14] , 379 indicating that our Korean SFTSV isolate possesses an equivalent degree of virulence to prior 380 Chinese isolates. The platelet counts in mice infected with 1 x 10 5 FFU of SFTSV 381 significantly declined up to 4 d after infection, and the mean platelet volumes of the infected 382 mice were significantly higher than those of control animals (S3 Fig B) , suggesting that 383 platelet destruction and the activation of platelet production simultaneously occur during 384 lethal infection [14] .
174
Preparation of recombinant proteins
385
To assess the protective efficacy of the DNA vaccine, groups of mice were immunized with 386 mock vector, pSFTSV, or pSFTSV-IL12 three times and then subcutaneously challenged 387 with a lethal dose (10 5 FFU/mouse) of SFTSV (Fig. 4) . All the mock-immunized mice antibodies against SFTSV in immune sera from mice immunized with either protein antigen 423 were significantly higher than those from Fc-immunized controls, when assessed by focus 424 reduction neutralization test (FRNT, Fig. 5B ). FRNT 50 titers of immune sera from mice 425 immunized with Gc-Fc (mean titer ± S.D. = 209 ± 140, n = 4) and Gn-Fc (mean titer ± S.D. = 426 929 ± 1,134, n = 4) were approximately five and twenty folds higher than those of Fc-427 immunized mice (mean titer ± S.D. = 42 ± 29, n = 4). It is also notable that FRNT 50 titers of 428 Gn-Fc immune sera were generally higher than those of Gc-Fc sera, although the difference 429 was not statistically significant. Finally, we examined the protective efficacy of the protein 430 vaccines against lethal infection with SFTSV ( Fig. 5C ). All the control mice immunized with Gc-Fc succumbed to death, they survived three days more than control mice and the 436 extension of median survival time was statistically significant (p = 0.0046). Given that immunization with Gn-Fc and Gc-Fc proteins can induce specific antibodies in 478 IFNAR KO mice (Fig. 5 Flt3L can significantly enhance CD8 T cell responses when fused with a target antigen and 484 promote persistent maintenance of antigen-specific CD8 T cells in vivo [16, 29] . In this study, 485 we also observed significant enhancement of Gn and NP-specific CD8 T cell responses, as 486 well as CD4 T cells, in the presence of IL-12 expression ( Fig. 3B and C) , which correlated 
